Shire Surges After FDA Approves Xiidra for Dry-Eye DiseaseBy
Xiidra is only treatment approved for both signs and symptoms
Analysts estimate sales will exceed $1 billion by 2022
Shire Plc rose to its highest level in 10 months in London after the U.S. Food and Drug Administration approved its Xiidra drops to treat dry-eye disease, the first treatment for the ailment to be approved in more than a decade.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.